TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29087443

Group type: COMPARATOR
Intervention: Usual treatment included in the programme (Group A)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Usual treatment plus attendance at self-help groups (Group B)
Number of subjects: 249
Study: 27884169

Group type: EXPERIMENTAL
Intervention: TeachTown: Basics, a computer-assisted intervention for students with autism
Number of subjects: 70
Study: 24948384

Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Parental control of feeding
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Parental pressure to eat
Number of subjects: 213

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 213
Study: 22116953

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 40% of heart rate reserve (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 60% of heart rate reserve (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Recreational activities (Group C)
Number of subjects: 48
Study: 20176444

Group type: EXPERIMENTAL
Intervention: Looming imagery condition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 72
Study: 19164818

Group type: EXPERIMENTAL
Intervention: Face-to-face support
Number of subjects: 66

Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (Face-to-face and Telephone)
Number of subjects: 66
Study: 16419568

Group type: EXPERIMENTAL
Intervention: SPECT scans after i.v. injection of 99mTc‐ECD of 0.3 mCi/kg b.m.
Number of subjects: 30
Study: 12591833

Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin twice daily for three months
Number of subjects: 2267

Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 2267
Study: 10654208

Group type: EXPERIMENTAL
Intervention: Lactate-based hemofiltration (group 1)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Acetate-based hemofiltration (group 2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Bicarbonate-based hemofiltration (group 3)
Number of subjects: 132
Study: 8562400

Group type: EXPERIMENTAL
Intervention: Intermittent claudication patients
Number of subjects: 617

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 617
Study: 9791239

Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-fluoridated toothpaste or control group not specified
Number of subjects: 0
Study: 2882776

Group type: EXPERIMENTAL
Intervention: Carteolol (beta-adrenoceptor blocker)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31726954

Group type: EXPERIMENTAL
Intervention: Circle of Security-Intensive (COS-I) intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 72
Study: 29072044

Group type: EXPERIMENTAL
Intervention: Focused shock wave therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy
Number of subjects: 32
Study: 27595443

Group type: EXPERIMENTAL
Intervention: IIV3 (trivalent inactivated influenza vaccine)
Number of subjects: 15044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15044
Study: 25539757

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy (CBT) for 4 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Individual psychology brief psychotherapy (IBPP) for 4 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + olanzapine (5 mg/day) for 3 months
Number of subjects: 95
Study: 22998148

Group type: EXPERIMENTAL
Intervention: Excision with inframammary incision (IFI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Excision with reduction mammoplasty incision (RMI)
Number of subjects: 22
Study: 19212708

Group type: EXPERIMENTAL
Intervention: Docetaxel (45 mg/m²) combined with 5‐FU/leucovorin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Irinotecan (180 mg/m²) combined with 5‐FU/leucovorin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 73
Study: 18991624

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg once daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg once daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg once daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All statins
Number of subjects: 94
Study: 15829533

Group type: EXPERIMENTAL
Intervention: Daily budesonide therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Intermittent treatment with budesonide
Number of subjects: 225

Group type: COMPARATOR
Intervention: Daily zafirlukast therapy
Number of subjects: 225
Study: 12860943

Group type: EXPERIMENTAL
Intervention: Antiandrogen withdrawal
Number of subjects: 184
Study: 10388668

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 9282581

Group type: EXPERIMENTAL
Intervention: Enalapril in combination with bronchodilators, diuretics, antibiotics and/or steroids
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment with diuretics, steroids and antibiotics alone
Number of subjects: 30
Study: 1713663

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg via epidural administration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.75 mg via epidural administration
Number of subjects: 16
Study: 6803519

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gliquidone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diet period
Number of subjects: 11
Study: 31121887

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 54
Study: 28774269

Group type: EXPERIMENTAL
Intervention: BCG vaccination (BCG 1331 SSI)
Number of subjects: 492
Study: 26606429

Group type: COMPARATOR
Intervention: LIFT
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: LIFT-plug
Number of subjects: 235
Study: 24711552

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg per day)
Number of subjects: 4560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4560
Study: 22011640

Group type: EXPERIMENTAL
Intervention: Blackcurrant (BC) juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 20329618

Group type: EXPERIMENTAL
Intervention: Zengjing Capsule No. 1 (ZJC1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wuzi Yanzong Pill (WYP)
Number of subjects: 72
Study: 17259038

Group type: EXPERIMENTAL
Intervention: Breast-feeding before, during, and after the injection
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine clinic procedure (no breast-feeding)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 66
Study: 15341217

Group type: EXPERIMENTAL
Intervention: Tensotremorography used to record voluntary forces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditions of visual feedback
Number of subjects: 0
Study: 11594407

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Cerivastatin 0.4 mg
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 1170
Study: 9772309

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7527565

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) 5‐hydroxyindoleacetic acid (5‐HIAA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) homovanillic acid (HVA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) 3‐methoxy‐4‐hydroxyphenylglycol (MHPG)
Number of subjects: 29
Study: 2658640

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1 g
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cefuroxime and Ceftazidime
Number of subjects: 46
Study: 51285

Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean 46.9 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 28
Study: 31648067

Group type: EXPERIMENTAL
Intervention: Interactive training model (group A)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Lecture-based training model (group B)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Video instruction training model (group C)
Number of subjects: 1282
Study: 30998223

Group type: EXPERIMENTAL
Intervention: Evident frustration comment
Number of subjects: 357

Group type: COMPARATOR
Intervention: Ambiguous comment
Number of subjects: 357
Study: 28069685

Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study: 26488347

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day (bulimic patients)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day (non-bulimic patients)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 94
Study: 23726516

Group type: EXPERIMENTAL
Intervention: Fat talk vignette
Number of subjects: 116

Group type: COMPARATOR
Intervention: Neutral vignette
Number of subjects: 116
Study: 21684391

Group type: EXPERIMENTAL
Intervention: Counselor arm (dedicated HIV counselors)
Number of subjects: 4855

Group type: COMPARATOR
Intervention: Provider arm (ED staff)
Number of subjects: 4855
Study: 18279106

Group type: EXPERIMENTAL
Intervention: Locteron 320 microg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Locteron 80 microg
Number of subjects: 27

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2b 80 microg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Locteron 20 microg and 80 microg
Number of subjects: 27
Study: 17146981

Group type: EXPERIMENTAL
Intervention: Adaptive allocation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing rules
Number of subjects: 0
Study: 15339529

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture plus opium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opium plus buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opium plus Han's instrument
Number of subjects: 0
Study: 11256775

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg twice daily)
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Dalteparin (7,500 IU)
Number of subjects: 1128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1128
Study: 9167318

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus cognitive behaviour therapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo plus cognitive behaviour therapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy alone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 8245990

Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation (6-12 weeks course)
Number of subjects: 174

Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 174
Study: 3766365

Group type: EXPERIMENTAL
Intervention: Group cardiac counseling and type A behavioral counseling (592 participants)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Group cardiac counseling (270 participants)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: No counseling (comparison group of 151 participants)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Experimental group (592 participants)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Control group (270 participants)
Number of subjects: 1013
Study: 31712335

Group type: EXPERIMENTAL
Intervention: Tailored and collaborative support for ACCHSs (early support)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-control (late support)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tailored support elements including training and feedback
Number of subjects: 22
Study: 29609153

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 97
Study: 26812515

Group type: EXPERIMENTAL
Intervention: Resistance training plus nutritional supplementation (R/N group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Resistance training alone (R group)
Number of subjects: 39
Study: 24448644

Group type: EXPERIMENTAL
Intervention: MDMA (0.75, 1.5 mg/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 or 40 IU)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 23140055

Group type: EXPERIMENTAL
Intervention: Moxibustion-20 min
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Moxibustion-40 min
Number of subjects: 84

Group type: COMPARATOR
Intervention: Medication (Ranitidine)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Moxibustion-20 min (1 month follow-up)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Moxibustion-40 min (1 month follow-up)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Medication (Ranitidine) (1 month follow-up)
Number of subjects: 84
Study: 20516228

Group type: EXPERIMENTAL
Intervention: Scaled response format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dichotomous categorical response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency information followed by abstract conditional reasoning problems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scaled response condition
Number of subjects: 0
Study: 19227193

Group type: EXPERIMENTAL
Intervention: Gender (male and female)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Level of vibration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Screen text/background colour
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Second order interaction (gender, vibration, colour)
Number of subjects: 14
Study: 16162054

Group type: EXPERIMENTAL
Intervention: Self-referenced feedback and n Ach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norm-referenced feedback and san Ach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n Ach and san Ach
Number of subjects: 0
Study: 12552508

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 1.2 g twice a day for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10651655

Group type: EXPERIMENTAL
Intervention: Eudragit-coated gelatine capsule containing 111In-labelled amberlite resin
Number of subjects: 10
Study: 9007589

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on the first day then 200 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amphotericin B/5-flucytosine (1.0-1.5 mg/kg body weight every other day and 3 x 2.5 g flucytosine/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amphotericin B/5-flucytosine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 72
Study: 1503286

Group type: EXPERIMENTAL
Intervention: Hygrophobic filter (Pall, Ultipor)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Heated humidifier (Dräger, Aquapor)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No warming device (Control group A)
Number of subjects: 75
Study: 6094438

Group type: EXPERIMENTAL
Intervention: Cefotaxime (50 mg/kg/dose every 6 h for 10 to 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol (standard doses)
Number of subjects: 30
Study: 31362183

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal application)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 13
Study: 29347866

Group type: EXPERIMENTAL
Intervention: Polydextrose-bar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-bar
Number of subjects: 0
Study: 26964689

Group type: EXPERIMENTAL
Intervention: High-fat breakfast (60% energy from fat)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-fat breakfast (20% energy from fat)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Macronutrient balanced breakfast (33% energy from fat)
Number of subjects: 32
Study: 25010881

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mixed with irreversible hydrocolloid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water mixed with irreversible hydrocolloid
Number of subjects: 20
Study: 22809972

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 58

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 58
Study: 21294410

Group type: EXPERIMENTAL
Intervention: Single-injection paravertebral block (PVB) with 0.3 ml/kg of 0.5% plain bupivacaine at T4 paravertebral space followed by general anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia only (Control)
Number of subjects: 20
Study: 18021336

Group type: COMPARATOR
Intervention: Praziquantel 20 mg/kg alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Praziquantel 20 mg/kg with ketoconazole 400 mg daily for 5 days
Number of subjects: 10
Study: 15863438

Group type: EXPERIMENTAL
Intervention: Mapleson A breathing system with a fresh gas flow of 9 litre min(‐1) (group A9)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mapleson D system with a fresh flow of 6 litre min(‐1) (group D6)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mapleson D system with a fresh flow of 3 litre min(‐1) (group D3)
Number of subjects: 65
Study: 11911101

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution intake during labour
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 201
Study: 9866670

Group type: EXPERIMENTAL
Intervention: Recommended levels of antidepressant treatment (doses recommended by the Agency for Health Care Policy and Research for 90 days or more)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Less-than-recommended levels of antidepressant treatment
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Minimum recommended levels of antidepressant treatment
Number of subjects: 358
Study: 7533825

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) - lenograstim 5 micrograms/kg/d between cycles
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control - VICE chemotherapy alone
Number of subjects: 65
Study: 2240750

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 91
Study: 388083

Group type: EXPERIMENTAL
Intervention: Adriamycin chemotherapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 29

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 29
Study: 30528166

Group type: EXPERIMENTAL
Intervention: Aquatic exercise training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Land-based exercise training
Number of subjects: 48
Study: 26884620

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for 24 h)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 106
Study: 25759407

Group type: EXPERIMENTAL
Intervention: TENS impulses at a strong but comfortable amplitude (median pulse amplitude 20 mA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: TENS impulses just above the sensory threshold (median pulse amplitude 7 mA)
Number of subjects: 70
Study: 23415433

Group type: EXPERIMENTAL
Intervention: Apple pectin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21812260

Group type: EXPERIMENTAL
Intervention: Tianwang buxin decoction (TWBXD) combined with dormancy hygiene education (DHE)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tianwang buxin decoction (TWBXD) alone
Number of subjects: 101
Study: 19748409

Group type: EXPERIMENTAL
Intervention: Group A: high-velocity low-amplitude manipulation, high-voltage pulse galvanic stimulation, counterforce bracing, ice, and exercises
Number of subjects: 6

Group type: COMPARATOR
Intervention: Group B: ultrasound, counterforce bracing, and exercise
Number of subjects: 6
Study: 16908918

Group type: EXPERIMENTAL
Intervention: Nurse management
Number of subjects: 406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study: 15128005

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative surgical margins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study: 11888823

Group type: EXPERIMENTAL
Intervention: Iodixanol (320mgI.ml(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iopromide (300mgI.ml(‐1))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physiologic saline (10ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iodixanol and Iopromide
Number of subjects: 10
Study: 9598509

Group type: EXPERIMENTAL
Intervention: Pretreatment with a gonadotropin‐releasing hormone agonist for 3 months before radical prostatectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Radical retropubic prostatectomy only (no pretreatment)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Negative surgical margin
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Hormonal pretreatment
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Hormonal pretreatment and radical prostatectomy
Number of subjects: 122
Study: 7934431

Group type: EXPERIMENTAL
Intervention: Sumatriptan (16 mg, subcutaneous administration)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3793199

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine (6 micrograms/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Domperidone (0.3 mg/kg)
Number of subjects: 20